PRN: Global Uveitis Market 2018 Forecasts & H2 2014 Therapeutic Pipeline Review in Research Reports

30/set/2014 20:22:00 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Uveitis Market 2018 Forecasts & H2 2014 Therapeutic Pipeline Review in Research Reports


DALLAS, September 30, 2014 /PRNewswire/ -- adds Global Uveitis Market 2014-2018 and Uveitis - Pipeline Review, H2 2014 research reports to the pharmaceuticals segment of its online business intelligence library. Published in May 2014 and August 2014, respectively, these reports are spread across 73 pages and 129 pages in their listed order.

The global Uveitis market is forecast to grow at 26.46% CAGR over the period 2013-2018. The Uveitis industry can be segmented into three divisions: the Americas, and the EMEA and APAC regions. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of uveitis. The Global Uveitis Market 2014-2018 research report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Uveitis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The Uveitis Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. This research features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation f! ollowing a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies profiled in Global Uveitis Market 2014-2018 research report include Abbvie Inc., Alcon Laboratories Inc., Allergan Inc., Bausch & Lomb Inc., Artielle ImmunoTherapeutics Inc., Enzo Biochem Inc., Hanall Pharmaceutical Co. Ltd., Lux Biosciences Inc., OphthaliX Inc., Regeneron Pharmaceuticals Inc., TopiVert Ltd., pSivida Corp., XOMA Corp. and Santen Pharmaceutical Co. Key Questions Answered in this Report include: What will the market size be in 2018 and what will the growth rate be?  What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? Order a copy of this Uveitis research report at .

The Uveitis Pipeline Review, H2 2014 market research report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of this Uveitis pipeline review report for H2 2014 covers: 

  • The report provides a snapshot of the global therapeutic landscape of Uveitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Order a copy of this research report at .

Explore more reports on the pharmaceuticals market at .

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.


Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441  

Connect With Us on:  

Facebook:  https: //


Twitter:  https: //


RSS/Feeds:  http: //

blog comments powered by Disqus è un servizio offerto da Factotum Srl